Hikma Pharmaceuticals (LSE:HIK), a former FTSE 100 member, now sits in the FTSE 250, according to Hargreaves Lansdown's constituent list as of 23 September 2026. For a multinational drugmaker reporting in US dollars, the change of index is largely a matter of Market Value ranking rather than a verdict on the Business itself.

The operational picture in 2026 has been steady. Interim results published on 6 August 2026 showed first-half Revenue up 4% to $1,728m and core operating profit up 9% to $405m. Management reiterated full-year guidance for revenue growth of 2–4% at constant currency and core operating profit of $720m–$770m.

The group also raised its Interim Dividend by 6% to 38 cents and has been buying back shares under a $250m programme. Relegation changes who holds the shares and how visible the company is to some investors; it does not in itself change Hikma's earnings, cash flows or strategy.

Why an Index Move Matters, and Why It Has Limits

When a company moves from the FTSE 100 to the FTSE 250, funds that track the Blue-Chip index generally have to sell, while trackers and mid-cap funds benchmarked to the FTSE 250 may become buyers. These flows can influence trading around the change, and some large global investors focus mainly on FTSE 100 names, which can reduce attention from that audience.

At the same time, FTSE 250 membership can bring a different set of investors who specialise in mid-cap companies, and a larger business in the index can stand out among its peers. The fundamental drivers of value, including product launches, pricing in US generics, margins and Capital allocation, are the same whichever index the shares belong to.

Three Businesses With Different Momentum

Hikma operates through three businesses: Injectables, Branded (focused on the Middle East and North Africa, or MENA) and Hikma Rx, its US generics arm. The first half of 2026 showed contrasting trends across them.

Branded was the standout. Revenue rose 15% to $502m and core operating profit increased 23%, with a core operating Margin of 32.5%. The company signed ten MENA partnerships in the period, adding to its portfolio in the region.

Injectables revenue was flat at $685m, while core operating profit fell 8%, giving a margin of 27.6%. Sales and Marketing spending in US Injectables rose 10%, and the company highlighted good US Demand in its April trading update. It also pointed to accelerating uptake of Tyzavan, its ready-to-use vancomycin bag.

Hikma Rx revenue was flat at $520m, but core operating profit rose 16%, with a margin of 20.6%. At its AGM trading update on 23 April 2026, the group said it had signed a device Partnership for its inhalation platform, which it describes as a key growth driver for the Rx business.

Profit, Cash and the Balance Sheet

Reported operating profit rose 30% to $336m, although the comparison was flattered by the first half of 2025, which was hit by a sodium oxybate legal settlement. Profit attributable to shareholders fell 6% to $223m, and basic Earnings per share were 103 cents against 108 cents a year earlier. On the company's core measure, earnings per share rose 5% to 128 cents, and core EBITDA was $463m.

Operating Cash Flow improved to $214m from $161m. Net Debt to core EBITDA stood at 1.9 times, up from 1.6 times at December 2025. Hikma (LSE:HIK) had repurchased $227m of shares under the $250m programme by 5 August 2026.

Investment in the pipeline continued. Research and Development spending rose 18%, the group made 48 submissions and it completed 43 launches in the first half. Generic and specialty drugmakers depend on a steady flow of approvals and launches to offset price erosion on older products, which makes this activity central to future growth.

Leadership Changes and Takeover Speculation

Hikma's Leadership changed in late 2025. Said Darwazah, the Executive Chairman, reassumed all chief executive responsibilities on 15 December 2025 after Riad Mishlawi stepped down by mutual agreement. Chief financial officer Khalid Nabilsi joined the Board with an expanded role. More recently, Tobias Hestler was appointed as a non-executive director on 7 August 2026.

Earlier in the year, press speculation about a possible bid prompted a statement from Brookfield Private Capital (DIFC). On 4 February 2026, Brookfield confirmed that it does not intend to make an offer for Hikma, a statement made under Rule 2.8 of the UK Takeover Code, which generally restricts it from bidding for a period unless certain circumstances apply.

Risks Facing the Group

The US generics market is competitive, and pricing pressure is a constant feature for companies like Hikma. The flat revenue in both Injectables and Hikma Rx in the first half shows that growth is not guaranteed, and the fall in Injectables core operating profit highlights the effect of higher Investment and competition on margins.

Leverage has risen, with net debt to core EBITDA moving from 1.6 times to 1.9 times over six months. While the company continues to generate cash, further buybacks, acquisitions or partnerships would need to be balanced against Balance Sheet capacity.

Pharmaceutical businesses also face regulatory and Manufacturing risks, including approval timelines and quality inspections, as well as exposure to currency movements in markets such as MENA. The gap between reported and core profit measures, including the effect of legal settlements, is a further reminder that headline figures can be affected by one-off items. The change in index could also bring periods of heightened share price Volatility as ownership adjusts.

What to Watch in the Months Ahead

Delivery against the reiterated guidance of 2–4% constant-currency revenue growth and core operating profit of $720m–$770m will be the main test for the second half. Investors will also be watching progress in the inhalation platform, uptake of Tyzavan and whether Branded can sustain its strong growth.

Hikma issued an announcement headed "R&D Investor Spotlight series" on 22 September 2026, underlining the importance it places on its pipeline. Completion of the $250m buyback and the direction of Leverage will also be of interest, as will any further steps by the board under the current leadership structure.

Conclusion

Hikma's move to the FTSE 250 reflects its position by market value rather than a deterioration in its results. The first half of 2026 brought higher revenue, higher core profit, a larger dividend and continued buybacks, alongside flat performance in two of its three businesses and rising leverage. How the group performs against its full-year targets will say more about its prospects than the index it belongs to.